Study of MEDI0382 in combination with Dapagliflozin and metformin in overweight/Obese Participants with Type 2 Diabetes

Study identifier:D5670C00007

ClinicalTrials.gov identifier:NCT03444584

EudraCT identifier:2017-002817-78

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in overweight/Obese Subjects with Type 2 Diabetes Mellitus Treated with Dapagliflozin and Metformin

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI0382, Placebo, Dapaglifozin, Dapaglifozin, Metformin, Metformin

Sex

All

Actual enrollment

49

Study type

Interventional

Age

18 Years - 115 Years

Date

Study Start Date: 08 May 2018
Primary Completion Date: 06 Dec 2018
Study Completion Date: 06 Dec 2018

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria